Wirtschaftlichkeit des Einsatzes von Irbesartan bei Patienten mit Typ-2 Diabetes, Hypertonie und Nephropathie in der Schweiz. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]

Details

Serval ID
serval:BIB_4EC3A2E56B91
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Wirtschaftlichkeit des Einsatzes von Irbesartan bei Patienten mit Typ-2 Diabetes, Hypertonie und Nephropathie in der Schweiz. [Health economic consequences of the use of irbesartan in patients with type 2 diabetes, hypertension and nephropathy in Switzerland]
Journal
Schweizerische Rundschau fur Medizin Praxis
Author(s)
Frei  A., Palmer  A. J., Burnier  M., Hess  B.
ISSN
1013-2058 (Print)
Publication state
Published
Issued date
03/2006
Volume
95
Number
11
Pages
401-8
Notes
Comparative Study
English Abstract
Journal Article --- Old month value: Mar 15
Abstract
The irbesartan in Diabetic Nephropathy Trial (IDNT) demonstrated that treatment of patients with type 2 diabetes, hypertension and nephropathy with irbesartan resulted in a 20% relative reduction of the composite endpoint of doubling serum creatinine, end-stage renal disease or death as compared with amlodipine and placebo (antihypertensive standard therapy). The objective of this study was to investigate the long-term health economic consequences of this treatment strategy in a Swiss health care setting. This analysis used a Markov model to simulate the progression of nephropathy, life-years and treatment costs over ten years for each of the three treatment options. In additon, sensitivity analyses were performed. Treatment with irbesartan will save CHF 22681/patient as compared with amlodipine and CHF 13847 as compared with standard therapy.
Keywords
Amlodipine/economics/therapeutic use Angiotensin II Type 1 Receptor Blockers/administration & dosage/*economics/*therapeutic use Antihypertensive Agents/administration & dosage/*economics/*therapeutic use Biphenyl Compounds/administration & dosage/*economics/*therapeutic use Calcium Channel Blockers/economics/therapeutic use Cohort Studies Cost Savings Costs and Cost Analysis Diabetes Mellitus, Type 2/complications/*drug therapy/*economics Diabetic Nephropathies/*drug therapy/*economics/mortality/surgery Disease Progression Follow-Up Studies Humans Hypertension/*drug therapy/*economics/etiology Kidney Failure, Chronic/etiology Kidney Transplantation/economics Markov Chains Multicenter Studies Placebos Randomized Controlled Trials Renal Dialysis Risk Sensitivity and Specificity Switzerland Tetrazoles/administration & dosage/*economics/*therapeutic use Time Factors
Pubmed
Create date
25/01/2008 12:55
Last modification date
20/08/2019 14:04
Usage data